Desirudin: A review of its use in the management of thrombotic disorders

Drugs

Volumn 60, Issue 3, 2000, Pages 679-700

  Matheson, A J ^a   Goa, K L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DESULFATOHIRUDIN; ENOXAPARIN; HEPARIN; RECOMBINANT HIRUDIN; STREPTOKINASE;

ALLERGY; ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ECONOMIC ASPECT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; THROMBIN TIME; THROMBOSIS; TOTAL HIP PROSTHESIS; UNSTABLE ANGINA PECTORIS;

ANGINA;

EID: 0033769928     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060030-00012     Document Type: Article

References (41)

1. Hirudins: Antithrombin anticoagulants
2. Past, present and future of hirudin
3. Pharmacological properties of hirudin and its derivatives: Potential clinical advantages over heparin
4. Biology of recombinant hirudin (CGP 39393): A new prospect in the treatment of thrombosis
5. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin
6. An objective perspective on recombinant hirudin: A new anticoagulant and antithromboric agent
7. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina: A multicenter trial
8. Hirudin: The promising antithrombotic
9. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
10. Hirudo medicinalis and hirudin
11. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group
12. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement
13. Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trial
14. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers
15. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
16. Open study of intravenous recombinant hirudin (CGP 39393) on platelet function and coagulation in healthy volunteers
17. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin
18. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration
19. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
20. Prevention of thromboembolism with use of recombinant hirudin - Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement
21. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
22. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial
23. Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: Experience from GUSTO-IIb
24. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
25. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
26. Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery
27. The most effective and safe prophylaxis of thromboembolic complications in patients undergoing total hip replacement with recombinant hirudin, Revasc(R), (CGP 39393), Ciba
28. Impact of hirudin versus heparin on mortality and (re)infarction in patients with acute coronary syndromes: A prospective meta-analysis of the GUSTO IIb and TIMI 9B trials
29. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO-IIb trial
30. Effect of desirudin treatment on diabetic patients with acute coronary syndromes
31. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial infarction (TIMI) 9A trial
32. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group)
33. Newer antithrombin agents in acute coronary syndromes
34. Hirudin versus heparin and low-molecular-weight heparin: And the winner is
35. Recombinant hirudins: An overview of recent developments
36. Direct thrombin inhibitors: Current status and future prospects
37. Deep vein thrombosis and total hip replacement surgery
38. Antithrombotic agents and thromboembolic disease
39. Future prospects of prophylaxis for deep vein thrombosis
40. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study